PX-3
# PX-3

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the $CB_1$ receptor with a binding affinity of $K_i$ = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.

## Legality

Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.

